BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Piyasa Fırsatı
FLOW Logosu
FLOW Fiyatı(FLOW)
$0.09263
$0.09263$0.09263
-0.41%
USD
FLOW (FLOW) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Trump Media received 260 BTC from Coinbase, worth $21 million.

Trump Media received 260 BTC from Coinbase, worth $21 million.

PANews reported on December 31 that, according to Emmett Gallic, Trump Media received 260 BTC (worth $21 million) from Coinbase between last night and early this
Paylaş
PANews2025/12/31 08:06
Sei Enhances Market Infrastructure with Real-Time Data and Transparency

Sei Enhances Market Infrastructure with Real-Time Data and Transparency

The post Sei Enhances Market Infrastructure with Real-Time Data and Transparency appeared on BitcoinEthereumNews.com. Rongchai Wang Dec 30, 2025 18:21 Sei introduces
Paylaş
BitcoinEthereumNews2025/12/31 08:12
FCA, crackdown on crypto

FCA, crackdown on crypto

The post FCA, crackdown on crypto appeared on BitcoinEthereumNews.com. The regulation of cryptocurrencies in the United Kingdom enters a decisive phase. The Financial Conduct Authority (FCA) has initiated a consultation to set minimum standards on transparency, consumer protection, and digital custody, in order to strengthen market confidence and ensure safer operations for exchanges, wallets, and crypto service providers. The consultation was published on May 2, 2025, and opened a public discussion on operational responsibilities and safeguarding requirements for digital assets (CoinDesk). The goal is to make the rules clearer without hindering the sector’s evolution. According to the data collected by our regulatory monitoring team, in the first weeks following the publication, the feedback received from professionals and operators focused mainly on custody, incident reporting, and insurance requirements. Industry analysts note that many responses require technical clarifications on multi-sig, asset segregation, and recovery protocols, as well as proposals to scale obligations based on the size of the operator. FCA Consultation: What’s on the Table The consultation document clarifies how to apply rules inspired by traditional finance to the crypto perimeter, balancing innovation, market integrity, and user protection. In this context, the goal is to introduce minimum standards for all firms under the supervision of the FCA, an essential step for a more transparent and secure sector, with measurable benefits for users. The proposed pillars Obligations towards consumers: assessment on the extension of the Consumer Duty – a requirement that mandates companies to provide “good outcomes” – to crypto services, with outcomes for users that are traceable and verifiable. Operational resilience: introduction of continuity requirements, incident response plans, and periodic testing to ensure the operational stability of platforms even in adverse scenarios. Financial Crime Prevention: strengthening AML/CFT measures through more stringent transaction monitoring and structured counterpart checks. Custody and safeguarding: definition of operational methods for the segregation of client assets, secure…
Paylaş
BitcoinEthereumNews2025/09/18 05:40